Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of votoplam in Huntington's disease
jRCT2031260068Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Sep 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in Huntington disease (HD) comparing Votoplam with Placebo (2 arms). Primary endpoint: Change from baseline in cUHDRS score. Started Sep 2026; status: recruiting.
02
Drugs
votoplam
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on jRCT2031260068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260068.